Devadas B, Freeman S K, Zupec M E, Lu H F, Nagarajan S R, Kishore N S, Lodge J K, Kuneman D W, McWherter C A, Vinjamoori D V, Getman D P, Gordon J I, Sikorski J A
Department of Medicinal and Structural Chemistry, G.D. Searle and Company, St. Louis, Missouri 63198, USA.
J Med Chem. 1997 Aug 1;40(16):2609-25. doi: 10.1021/jm970094w.
A new class of antifungal agents has been discovered which exert their activity by blockade of myristoylCoA: protein N-myristoyltransferase (NMT; EC 2.1.3.97). Genetic experiments have established that NMT is needed to maintain the viability of Candida albicans and Cryptococcus neoformans,the two principal causes of systemic fungal infections in immunocompromised humans. Beginning with a weak octapeptide inhibitor ALYASKLS-NH2 (2, Ki = 15.3 +/- 6.4 microM), a series of imidazole-substituted Ser-Lys dipeptide amides have been designed and synthesized as potent and selective inhibitors of Candida albicans NMT. The strategy that led to these inhibitors evolved from the identification of those functional groups in the high-affinity octapeptide substrate GLYASKLS-NH2 1a necessary for tight binding, truncation of the C-terminus, replacement of the four amino acids at the N-terminus by a spacer group, and substitution of the glycine amino group with an N-linked 2-methylimidazole moiety. Initial structure-activity studies led to the identification of 31 as a potent and selective peptidomimetic inhibitor with an IC50 of 56 nM and 250-fold selectivity versus human NMT. 2-Methylimidazole as the N-terminal amine replacement in combination with a 4-substituted phenacetyl moiety imparts remarkable potency and selectivity to this novel class of inhibitors. The (S,S) stereochemistry of serine and lysine residues is critical for the inhibitory activity, since the (R,R) enantiomer 40 is 10(3)-fold less active than the (S,S) isomer 31. The inhibitory profile exhibited by this new class of NMT ligands is a function of the pKa of the imidazole substituent as illustrated by the benzimidazole analog 35 which is about 10-fold less potent than 31. The measured pKa (7.1 +/- 0.5) of 2-methylimidazole in 31 is comparable with the estimated pKa (approximately 8.0) of the glycyl residue in the high-affinity substrate 1a. Groups bulkier than methyl, such as ethyl, isopropyl, or iodo, at the imidazole 2-position have a detrimental effect on potency. Further refinement of 31 by grafting an alpha-methyl group at the benzylic position adjacent to the serine residue led to 61 with an IC50 of 40 nM. Subsequent chiral chromatography of 61 culminated in the discovery of the most potent Candida NMT inhibitor 61a reported to date with an IC50 of 20 nM and 400-fold selectivity versus the human enzyme. Both 31 and 61a are competitive inhibitors of Candida NMT with respect to the octapeptide substrate GNAASARR-NH2 with Ki(app) = 30 and 27 nM, respectively. The potency and selectivity displayed by these inhibitors are dependent upon the size and orientation of the alpha-substituent. An alpha-methyl group with the R configuration corresponding to the (S)-methyl-4-alanine in 2 confers maximum potency and selectivity. Structural modification of 31 and 61 by appending an (S)-carboxyl group beta to the cyclohexyl moiety provided the less potent tripeptide inhibitors 73a and 73b with an IC50 of 1.45 +/- 0.08 and 0.38 +/- 0.03 microM, respectively. However, these tripeptides (73a and 73b) exhibited a pronounced selectivity of 560- and 2200-fold versus the human NMT. More importantly 73a displayed fungistatic activity against C albicans with an EC50 of 51 +/- 17 microM in cell culture. Compound 73b also exhibited a similar antifungal activity. An Arf protein gel mobility shift assay for monitoring intracellular myristoylation revealed that a single dose of 200 microM of 73a or 73b produced < 50% reduction in Arf N-myristoylation, after 24 and 48 h, consistent with their fungistatic rather than fungicidal activity. In contrast, the enantiomer 73d which had an IC50 > 1000 microM against C. albicans NMT did not exhibit antifungal activity and produced no detectable reduction in Arf N-myristoylation in cultures of C. albicans. These studies confirm that the observed antifungal activity of 73a and 73b is due to the attenuation of NMT activity and that NMT represents an attractive tar
已发现一类新型抗真菌剂,它们通过阻断肉豆蔻酰辅酶A:蛋白质N-肉豆蔻酰转移酶(NMT;EC 2.1.3.97)发挥其活性。遗传学实验已证实,NMT是维持白色念珠菌和新型隐球菌生存能力所必需的,这两种菌是免疫功能低下人群系统性真菌感染的两个主要病因。从弱八肽抑制剂ALYASKLS-NH2(2,Ki = 15.3±6.4 microM)开始,设计并合成了一系列咪唑取代的丝氨酸-赖氨酸二肽酰胺,作为白色念珠菌NMT的强效和选择性抑制剂。导致这些抑制剂的策略源于对高亲和力八肽底物GLYASKLS-NH2 1a中紧密结合所必需的那些官能团的鉴定,C端截短,用间隔基团取代N端的四个氨基酸,以及用N-连接的2-甲基咪唑部分取代甘氨酸氨基。初步的构效关系研究导致鉴定出31作为一种强效和选择性拟肽抑制剂,其IC50为56 nM,对人NMT的选择性为250倍。2-甲基咪唑作为N端胺取代基与4-取代苯乙酰部分相结合,赋予了这类新型抑制剂显著的效力和选择性。丝氨酸和赖氨酸残基的(S,S)立体化学对抑制活性至关重要,因为(R,R)对映体40的活性比(S,S)异构体31低10³倍。这类新型NMT配体表现出的抑制特征是咪唑取代基pKa的函数,如苯并咪唑类似物35所示,其效力比31低约10倍。31中2-甲基咪唑的实测pKa(7.1±0.5)与高亲和力底物1a中甘氨酰残基的估计pKa(约8.0)相当。咪唑2位上比甲基更大的基团,如乙基、异丙基或碘,对效力有不利影响。通过在与丝氨酸残基相邻的苄基位置接上一个α-甲基对31进行进一步优化,得到了IC50为40 nM的61。随后对61进行手性色谱分离,最终发现了迄今为止报道的最有效的白色念珠菌NMT抑制剂61a,其IC50为20 nM,对人酶的选择性为400倍。31和61a都是白色念珠菌NMT相对于八肽底物GNAASARR-NH2的竞争性抑制剂,Ki(app)分别为30和27 nM。这些抑制剂表现出的效力和选择性取决于α-取代基的大小和取向。与2中(S)-甲基-4-丙氨酸对应的具有R构型的α-甲基赋予最大的效力和选择性。通过在环己基部分β位接上一个(S)-羧基对31和61进行结构修饰,得到了效力较低的三肽抑制剂73a和73b,其IC50分别为1.45±0.08和0.38±0.03 microM。然而,这些三肽(73a和73b)对人NMT表现出560倍和2200倍的显著选择性。更重要的是,73a在细胞培养中对白色念珠菌表现出抑菌活性,EC50为51±17 microM。化合物73b也表现出类似的抗真菌活性。用于监测细胞内肉豆蔻酰化的Arf蛋白凝胶迁移率变动分析表明,单剂量200 microM的73a或73b在24和48小时后使Arf N-肉豆蔻酰化降低<50%,这与其抑菌而非杀菌活性一致。相比之下,对白色念珠菌NMT的IC50>1000 microM的对映体73d在白色念珠菌培养物中未表现出抗真菌活性,也未使Arf N-肉豆蔻酰化出现可检测到的降低。这些研究证实,观察到的73a和73b的抗真菌活性是由于NMT活性的减弱,并且NMT是一个有吸引力的靶点。